Study design overview
IBS
INFLAMMATION
MY-IBS was a randomized 2-group controlled trial conducted at the University of Calgary in Alberta, Canada, from March 2021 to December 2022. Participants were not blinded to trial arms. Eligible participants diagnosed with IBS based on Rome IV (Individuals across Canada were eligible to participate. Participants were recruited between March and October 2021 and identified through (i) gastroenterology clinics across Calgary, Alberta, (ii) a previous survey where participants indicated an interest in this study and provided consent to be contacted, (iii) social media, (iv) self-referrals, (v) Canadian Association of Gastroenterologists monthly newsletter, and (vi) the IMAGINE (Inflammation, Microbiome and Alimentation Gastrointestinal and Neuropsychiatric Effects) cohort study at the University of Calgary. The University of Calgary Conjoint Health Research Ethics Board approved this study (ID: REB20-0084).